McKnight’s Senior Living March 8, 2024
(HealthDay News) — The US Food and Drug Administration has approved Wegovy (semaglutide) for the prevention of myocardial infarction, stroke and cardiovascular death in patients with obesity or overweight.
In one multinational study involving more than 17,600 people, participants received either injected Wegovy or a placebo injection. All participants also received standard-of-care management of their blood pressure and cholesterol plus counseling on exercise and healthy eating.
“Wegovy significantly reduced the risk of major adverse cardiovascular events (cardiovascular death, heart attack, and stroke), which occurred in 6.5% of participants who received Wegovy compared to 8% of participants who received placebo,” the FDA said.
It is thought that this expanded approval from the FDA could remove barriers from insurance companies when it...
Today's Sponsors
Today's Sponsor